

Fig. S1




Figure S1. Assessment of the specificity of IDO1 and IDO2 antibodies. Western blotting of purified IDO2 protein (lane 1), purified IDO1 protein (lane 2) and lysate of human CD34⁺ cells, immunomagnetically purified (Milteny Biotec; lane 3). IDO1 and IDO2 antibodies are specific for IDO1 and IDO2 purified protein, respectively (A and B). Human CD34⁺ cells represent the negative control for IDO1 and IDO2 expression. Representative results of 3 independent experiments.

Fig. S2




Figure S2. Assessment of the selectivity of 1-MT-L and 1-MT-D. Quantification of T cells coexpressing CD4, CD25 and Foxp3 after the coculture of autologous CD3⁺ T cells with DC treated with CTR-siRNA or IDO1- or IDO2-specific siRNA, in the presence or absence of 1-MT-L and 1-MT-D (1 mM). Representative results of 5 independent experiments.